5-Formyl-2-Acidum Furanboronic CAS 27329-70-0 Puritas >98.0% (HPLC) Imago Featured

5-Formyl-2-Acid furanboronic CAS 27329-70-0 Puritas >98.0% (HPLC)

Description:

Nomen chemicum: 5-Formyl-2-Acidi Furanboronic

CAS: 27329-70-0

Puritas: >98.0% (HPLC)

Aspectus: Off-White ad lux Yellow pulveris

Ditosylate Monohydratorum

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 5-Formyl-2-Acidi Furanboronici (CAS: 27329-70-0) cum qualitate alta.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase 5-Formyl-2-Acid furanboronic;Please contact: alvin@ruifuchem.com

Lapatinib intermedia:

Lapatinib Base	CAS 231277-92-2
Lapatinib Ditosylate Monohydrate	CAS 388082-78-8
Sodium Methanesulfinate	CAS 20277-69-4
3-Chloro-4-(3-Fluorobenzyloxy)aniline	CAS 202197-26-0
2-Aminoethyl Methyl Sulfone Hydrochloridis	CAS 104458-24-4
4-Chloro-6-Iodoquinazoline	CAS 98556-31-1
6-Iodo-4-Hydroxyquinazoline	CAS 16064-08-7
5-Formyl-2-Acidi Furanboronic	CAS 27329-70-0
5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde	CAS 231278-84-5

Chemical Properties:

Nomen chemicum	5-Formyl-2-Acidi Furanboronic
Synonyma	5-Formylfuran-2-Boronic Acidum;5-Formyl-2-Acid furanylboronic;2-Formylfuran-5-boronic Acidum;(5-Formylfuran-2-yl) Acidum boronicum;(5-Formyl-2-Furyl) Acidum boronicum;FFBA
Stock Status	In Stock, Commercial Productio
CAS Number	27329-70-0
Formulae hypotheticae	C5H5BO4
M. Pondus	139.90 g/mol
Liquescens punctum	136℃(decl.)
Density	1.36±0.10 g/cm3
Sensitiva	Aer Sensitiva
Aqua Solubility	Insolubilis in aqua
COA & MSDS	Praesto
Sample	Praesto
Origin	Shanghai, China
Brand	Ruifu Chemical

Specifications:

Items	Signa inspectionis	Proventus
Aspectus	Off-White ad lux Yellow pulveris	Lumen Yellow Pulvis
Aquae Caroli Fischer	<0.50%	0.11%
Puritas / Analysis Methodus	>98.0% (HPLC)	99.79%
Infrared Imaginis	Congruunt Structure	Obsequitur
1H NMR Imaginum	Congruunt Structure	Obsequitur
conclusio	Productum probatum est et cum datis specificationibus obsequitur

Sarcina / at /naviportans:

Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Aere sensitivo.Continentem arcte clausam et in frigido, sicco et bene ventilato horreis a substantiis incompossibilibus repone.Copia ab aere, humore et agentibus oxidizing.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

27329-70-0 - Salutis Information:

Periculum Codes
R34 - Causae ardet
R36/37/38 - Irritando ad oculos, systema respiratorium et cutem.
Salus Descriptio
S26 - In contactu cum oculis, statim cum aqua multa ablue et consilium medicinae quaeras.
S36/37/39 - Indumentum tutelae idoneum, caestus et oculi/facies tutelam gerunt.
S45 - In casu casu vel si bene sentis, consilium medicinae statim quaere (titalam quoties fieri potest).
S37/39 - gere idoneam caestus et oculum/faciem praesidio
S27 - Exue illico omnem vestem contaminatam.
UN IDs UN 3261 8/PG 3
WGK Germania 3
TSCA No
HS Codicis 2932190090
Aleam Nota Irritant
Aleam Class Irritantem, ut frigoris
Stipare Group

27329-70-0 - Applicatio:

5-Formyl-2-Franboronic Acidum (CAS: 27329-70-0) est acidum boricum medium, in medicina et aliis agris late adhibitum.Composita acidum boricum agere cum aromatibus chlorinis, bromine vel iodido et olefino in Suzuki, eo quod varias circulos coniungens et producta amni valde ditissima sunt.

5-Formyl-2-Acid furanboronicum medium Lapatinib (CAS: 231277-92-2) / Lapatinib Ditosylate Monohydratum (CAS: 388082-78-8).Lapatinib (lapatinib), nomen artis Tykerb, est oralis convertibilis moleculae tyrosinae kinasi minoris inhibitoris pro HER-1/ HER-2.Lapatinib aliam mechanismum actionis habet ab anticorpore monoclonali probato humanato medicamento Herceptin, quod cellam proliferation deorsum ordinare potest per iter duplicem interclusionem HER-1/ HER-2.Lapatinib in compositione cum Capecitabine apta est curationi carcinomatis progressi vel metastatici aegroti cum HER2(ErbB-2 overexpression) et praecedente curatione inter anthracyclinos, paclitaxel et trastuzumab.